AVDL AVADEL PHARMACEUTICALS PLC Earnings Reports 8-K Filing 2025 - Financial Update Avadel Pharmaceuticals expects approximately $50 million in net product revenue from LUMRYZ for Q4 2024 and about $169 million for the full year, with cash reserves around $73 million as of December 31, 2024; the REVITALYZ study for idiopathic hypersomnia is set to complete in H2 2025.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC